Differential Retinal Protein Expression in Primary and Secondary Retinal Ganglion Cell Degeneration Identified by Integrated SWATH and Target-Based Proteomics.
ganglion cell
mass spectrometry
neurodegeneration
optic nerve
protein
proteomics
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
10 Aug 2021
10 Aug 2021
Historique:
received:
22
05
2021
revised:
06
08
2021
accepted:
08
08
2021
entrez:
27
8
2021
pubmed:
28
8
2021
medline:
16
9
2021
Statut:
epublish
Résumé
To investigate the retinal proteins associated with primary and secondary retinal ganglion cell (RGC) degeneration and explore their molecular pathways, SWATH label-free and target-based mass spectrometry was employed to identify the proteomes in various retinal locations in response to localized optic nerve injury. Unilateral partial optic nerve transection (pONT) was performed on adult Wistar rats and their retinas were harvested 2 weeks later. To confirm the separation of primary and secondary RGC degeneration, immunohistochemistry of RNA binding protein with multiple splicing (RBPMS) and glial fibrillary acidic protein (GFAP) was performed on retinal whole-mounts. Retinal proteomes in the temporal and nasal quadrants were evaluated with high resolution hybrid quadrupole time-of-flight mass spectrometry (QTOF-MS), and SWATH-based acquisition, and their expression was compared to the corresponding retinal quadrant in contralateral control eyes and further validated by multiple reaction monitoring mass spectrometry (MRM-MS). A total of 3641 proteins (FDR < 1%) were identified using QTOF-MS. The raw data are available via ProteomeXchange with the identifier PXD026783. Bioinformatics data analysis showed that there were 37 upregulated and 25 downregulated proteins in the temporal quadrant, whereas 20 and five proteins were upregulated and downregulated, respectively, in the nasal quadrant, respectively (
Identifiants
pubmed: 34445296
pii: ijms22168592
doi: 10.3390/ijms22168592
pmc: PMC8395271
pii:
doi:
Substances chimiques
Eye Proteins
0
Proteome
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Research to Prevent Blindness
ID : Unrestricted
Organisme : GRF grant (Hong Kong, SAR, China).
ID : 251006/14M
Références
J Proteomics. 2018 Jun 15;181:1-15
pubmed: 29572162
Prog Retin Eye Res. 2012 Nov;31(6):702-19
pubmed: 22871543
Int J Mol Sci. 2020 Sep 04;21(18):
pubmed: 32899874
Invest Ophthalmol Vis Sci. 2011 Dec 28;52(13):9694-702
pubmed: 22110060
J Cell Biochem. 2020 Jul 21;:
pubmed: 32692886
Int J Mol Sci. 2021 Apr 29;22(9):
pubmed: 33946922
Neuroscientist. 2020 Apr;26(2):134-155
pubmed: 31092147
Invest Ophthalmol Vis Sci. 2003 Jan;44(1):154-9
pubmed: 12506068
J Neurol Sci. 1978 Jan;35(1):147-55
pubmed: 624958
Nat Neurosci. 2011 Oct 26;14(11):1363-8
pubmed: 22030546
Chem Biol Interact. 2020 Nov 1;331:109249
pubmed: 32980322
Mol Cell Neurosci. 1997;9(2):116-31
pubmed: 9245496
Nucleic Acids Res. 2002 Jan 1;30(1):42-6
pubmed: 11752249
J Neurotrauma. 1993 Fall;10(3):349-62
pubmed: 8258846
Cell Death Discov. 2016 May 23;2:16031
pubmed: 27551521
Genome Res. 2013 Nov;23(11):1885-93
pubmed: 23934932
Pharmacol Toxicol. 1996 Jan;78(1):12-7
pubmed: 8685080
J Neurotrauma. 2010 Feb;27(2):439-52
pubmed: 19852581
Hum Mol Genet. 2017 Oct 1;26(R2):R139-R150
pubmed: 28977448
Mod Pathol. 2019 Jul;32(7):967-976
pubmed: 30760857
Apoptosis. 2019 Oct;24(9-10):687-702
pubmed: 31256300
Invest Ophthalmol Vis Sci. 2007 Dec;48(12):5539-48
pubmed: 18055803
Arch Ophthalmol. 1981 Apr;99(4):635-49
pubmed: 6164357
Nat Med. 1997 Jan;3(1):73-6
pubmed: 8986744
Nat Genet. 2000 May;25(1):25-9
pubmed: 10802651
Antioxidants (Basel). 2020 Aug 17;9(8):
pubmed: 32824523
Exp Eye Res. 2020 Feb;191:107922
pubmed: 31923413
Prog Neurobiol. 2013 Jun;105:24-48
pubmed: 23567504
Prog Retin Eye Res. 2011 Mar;30(2):81-114
pubmed: 21112411
Nat Biotechnol. 2011 Jun 26;29(7):653-8
pubmed: 21706016
J Biol Chem. 2008 Dec 12;283(50):34954-65
pubmed: 18936101
Exp Eye Res. 2010 Aug;91(2):127-34
pubmed: 19951705
PLoS One. 2013 Jun 11;8(6):e65710
pubmed: 23776532
J Cell Biol. 2005 May 23;169(4):669-80
pubmed: 15911881
PLoS One. 2018 Feb 9;13(2):e0192348
pubmed: 29425209
Prog Retin Eye Res. 1999 Jan;18(1):39-57
pubmed: 9920498
Mol Vis. 2001 Aug 15;7:192-201
pubmed: 11509915
Ophthalmic Res. 2021;64(3):345-355
pubmed: 33454713
Mol Med Rep. 2019 Sep;20(3):2734-2742
pubmed: 31524249
Aging Cell. 2018 Aug;17(4):e12710
pubmed: 29730901
Chem Rev. 2019 Jan 9;119(1):293-321
pubmed: 30152694
Invest Ophthalmol Vis Sci. 2002 Apr;43(4):1088-94
pubmed: 11923250
Int J Mol Sci. 2020 Oct 01;21(19):
pubmed: 33019767
Int Rev Neurobiol. 2012;105:1-17
pubmed: 23206593
Genome Res. 2001 Aug;11(8):1425-33
pubmed: 11483584
Nucleic Acids Res. 2019 Jan 8;47(D1):D442-D450
pubmed: 30395289
Eur J Neurosci. 1994 May 1;6(5):712-24
pubmed: 8075816
Proteomics. 2017 Feb;17(3-4):
pubmed: 28127880
J Neurotrauma. 1995 Oct;12(5):791-814
pubmed: 8594208
Invest Ophthalmol Vis Sci. 2010 Feb;51(2):1052-8
pubmed: 19737887
J Neurol Sci. 2017 Apr 15;375:430-441
pubmed: 28320183
Invest Ophthalmol Vis Sci. 2001 Apr;42(5):975-82
pubmed: 11274074
J Biol Chem. 2004 Jan 16;279(3):2046-52
pubmed: 14585841
Exp Neurol. 2001 Jun;169(2):438-48
pubmed: 11358457
Nucleic Acids Res. 2000 Jan 1;28(1):27-30
pubmed: 10592173
Arch Ophthalmol. 1997 Jun;115(6):752-6
pubmed: 9194727
Invest Ophthalmol Vis Sci. 2010 Mar;51(3):1659-65
pubmed: 19875648
Invest Ophthalmol Vis Sci. 2003 Aug;44(8):3388-93
pubmed: 12882786
Prog Retin Eye Res. 2013 Mar;33:28-39
pubmed: 23098688
Invest Ophthalmol Vis Sci. 2009 Jan;50(1):424-31
pubmed: 18775855
Biochem Soc Trans. 2006 Dec;34(Pt 6):1287-90
pubmed: 17073803
Prog Retin Eye Res. 2019 Nov;73:100769
pubmed: 31301400
Front Cell Neurosci. 2017 Jul 19;11:201
pubmed: 28769762